Assembly Biosciences, Inc. (ASMB) AI Stock Analysis

Assembly Biosciences, Inc., founded in 2005 and headquartered in South San Francisco, California, is a clinical-stage biotechnology company developing therapeutic candidates for hepatitis B virus (HBV) infection. Its lead candidate, Vebicorvir, has completed Phase 2 clinical trials for chronic HBV. The company's pipeline also features ABI-H3733, which finished Phase 1a clinical trials, and ABI-4334, which is currently in pre-clinical studies. Assembly Biosciences has formed collaboration agreements with BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc. to assess triple combination treatments. It also maintains strategic licensing agreements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC.

Assembly Biosciences has experienced sharp fluctuations in revenue, swinging from $79.1M in FY2020 down to $6.3M in FY2021 before recovering to $28.5M in FY2024 and $72.3M in FY2025, which marked 153.5% annual growth. Over the 5-year period from FY2019 to FY2025, revenue delivered a compound annual growth rate of 35.3%. Operating margin improved from -159.3% in FY2024 to -16.8% in FY2025, helping narrow net losses from -$40.2M to -$6.1M. In the latest quarter ended June 30, 2026, quarterly revenue grew 38.9% year-over-year, while trailing twelve-month revenue reached $74.8M with an operating margin of -47.4%.

As of June 30, 2026, Assembly Biosciences maintained a strong liquidity profile with $320.4M in cash and short-term investments and total debt of $2.4M, resulting in net cash of $318.0M. Its current ratio stood at 13.99, while the debt-to-equity ratio was 0.01 against shareholders' equity of $305.6M. Cash flow remains negative due to clinical operations, with FY2025 operating cash flow of -$41.1M and free cash flow of -$41.2M. Capital expenditures were modest at $66,000 in FY2025, while the 5-year share count change was 313.7%.

At a share price of $20.09, Assembly Biosciences trades at an enterprise value of $200.2M and a market capitalization of $409.0M. The stock trades at a trailing price-to-earnings ratio of 19.3x, below the 24.6x median of its US-listed Healthcare peers, but carries a forward price-to-earnings multiple of 500.0x compared to the peer median of 17.3x. Its price-to-sales ratio is 5.5x versus the peer median of 4.1x, while its EV-to-EBITDA stands at 0.4x against the peer median of 12.0x. Over the past year, ASMB shares fell 30.9%, trailing the S&P 500 return of 16.8%.

All 5 analysts covering Assembly Biosciences rate the stock as a Strong Buy, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell recommendations. The mean price target is $52.00, representing a 158.8% premium over the last closing price of $20.09. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.12 on revenue of $63.4M. For the following fiscal year, 4 analysts estimate revenue will drop 46.2% to $34.1M with EPS declining to -$2.57. Assembly Biosciences has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Assembly Biosciences, Inc. (ASMB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ASMB income statement, ASMB balance sheet, ASMB key metrics, ASMB analyst forecast, ASMB chart. See the ASMB stock overview for the latest quote and news.